Literature DB >> 25621807

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis.

B Dhakal1, A D'Souza1, C Arce-Lara1, M Pasquini1, W Saber1, F Falvo1, J Esselman1, K Zellner1, T Fenske1, P N Hari1, M Hamadani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25621807     DOI： 10.1038/bmt.2014.318

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

2.  Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection.

Authors:  Qaiser Bashir; Lauren A Langford; Simrit Parmar; Richard E Champlin; Muzaffar H Qazilbash
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

Review 3.  Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.

Authors:  Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742

4.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 5.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

6.  Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

Authors:  S Parmar; P Kongtim; R Champlin; Y Dinh; Y Elgharably; M Wang; Q Bashir; J J Shah; N Shah; U Popat; S A Giralt; R Z Orlowski; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

7.  Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis.

Authors:  Cesare Perotti; Claudia Del Fante; Gianluca Viarengo; Stefano Perlini; Monia Vezzoli; Giuseppe Rodi; Alessandra Palo; Paola Bergamaschi; Laura Salvaneschi
Journal:  Transfusion       Date:  2005-11       Impact factor: 3.157

8.  Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.

Authors:  F Awan; S T Kochuparambil; D E Falconer; A Cumpston; S Leadmon; K Watkins; D Deremer; A Jillella; M Craig; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

Review 9.  How I treat amyloidosis.

Authors:  Raymond L Comenzo
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

10.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245
View more
  2 in total

1.  An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.

Authors:  Talha Badar; Binod Dhakal; Aniko Szabo; Anand Padmanabhan; Bryon D Johnson; Sarah Heidtke; Jean Esselmann; Saurabh Chhabra; Mehdi Hamadani; Parameswaran Hari; Anita D'Souza
Journal:  J Clin Apher       Date:  2019-09-30       Impact factor: 2.821

2.  Rapid prediction of stem cell mobilization using volume and conductivity data from automated hematology analyzers.

Authors:  Carlos H Villa; Thomas Porturas; Mary Sell; Mark Wall; Gene DeLeo; Jenna Fetters; Sam Mignono; Leah Irwin; Wei-Ting Hwang; Una O'Doherty
Journal:  Transfusion       Date:  2017-12-11       Impact factor: 3.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.